Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: From risk factor identification to risk factor intervention

Joint Bone Spine

Volumn 77, Issue 1, 2010, Pages 6-12

  Bardou, Marc ^a,b   Barkun, Alan N ^c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Aspirin; Gastrointestinal bleeding; Gastroprotection; Nonsteroidal anti inflammatory drugs; NSAID; Proton pump inhibitors; Ulcer

Indexed keywords

ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ALCOHOL CONSUMPTION; CIGARETTE SMOKING; DRUG HALF LIFE; GASTROINTESTINAL TOXICITY; GENDER; HELICOBACTER INFECTION; HUMAN; PEPTIC ULCER; PROPHYLAXIS; RISK BENEFIT ANALYSIS; SENESCENCE; SHORT SURVEY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HUMANS; MALE; PEPTIC ULCER; PROTON PUMP INHIBITORS; RISK ASSESSMENT; RISK FACTORS; RISK MANAGEMENT;

EID: 73449116676     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.11.008     Document Type: Short Survey

References (63)

1. Clinard F., Sgro C., Bardou M., et al. Non-steroidal anti-inflammatory drug prescribing patterns in general practice: comparison of a general practitioner-based survey and a pharmacy-based survey in France. Pharmacoepidemiol Drug Saf 10 (2001) 329-338
2. Merle V., Thiefin G., and Czernichow P. Epidemiology of gastroduodenal complications associated with nonsteroidal anti-inflammatory drug use. Gastroenterol Clin Biol 28 3 (2004) C27-C36
3. van der Hooft C.S., Sturkenboom M.C., van Grootheest K., et al. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 29 (2006) 161-168
4. Pirmohamed M., James S., Meakin S., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329 (2004) 15-19
5. Pouyanne P., Haramburu F., Imbs J.L., et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 320 (2000) 1036
6. Franceschi M., Scarcelli C., Niro V., et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf 31 (2008) 545-556
7. Lanas A., Perez-Aisa M.A., Feu F., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 100 (2005) 1685-1693
8. Abraham N.S., Castillo D.L., and Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther 28 (2008) 97-106
9. Vonkeman H.E., Klok R.M., Postma M.J., et al. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs. Drugs Aging 24 (2007) 681-690
10. Garcia Rodriguez L.A., and Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132 (2007) 498-506
11. Talamini G., Tommasi M., Amadei V., et al. Risk factors of peptic ulcer in 4943 inpatients. J Clin Gastroenterol 42 4 (2008) 373-380
12. Udd M., Miettinen P., Palmu A., et al. Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case-control study. Scand J Gastroenterol 42 (2007) 1395-1403
13. Rahme E., Bardou M., Dasgupta K., et al. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 46 (2007) 265-272
14. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55 (2006) 1731-1738
15. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56 (2007) 772-781
16. Huang J.Q., Sridhar S., and Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (2002) 14-22
17. Papatheodoridis G.V., Sougioultzis S., and Archimandritis A.J. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 4 (2006) 130-142
18. Kaufman D.W., Kelly J.P., Wiholm B.E., et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol 94 (1999) 3189-3196
19. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000) 834-839
20. Hallas J., Dall M., Andries A., et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 333 (2006) 726
21. Lanas A., Serrano P., Bajador E., et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 112 (1997) 683-689
22. van Oijen M.G., Dieleman J.P., Laheij R.J., et al. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol 6 (2008) 309-313
23. Kelly J.P., Kaufman D.W., Jurgelon J.M., et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348 (1996) 1413-1416
24. Lewis J.D., Strom B.L., Localio A.R., et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf 17 (2008) 328-335
25. Johnell K., and Fastbom J. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study. Clin Drug Investig 28 (2008) 687-695
26. Thomopoulos K.C., Mimidis K.P., Theocharis G.J., et al. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome. World J Gastroenterol 11 (2005) 1365-1368
27. Holvoet J., Terriere L., Van Hee W., et al. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study. Gut 32 (1991) 730-734
28. Silvani M.C., Motola D., Poluzzi E., et al. Gastro-intestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy. Eur J Clin Pharmacol 62 (2006) 235-241
29. Patrono C., Garcia Rodriguez L.A., Landolfi R., et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005) 2373-2383
30. Cryer B., and Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117 (1999) 17-25
31. Thiefin G., Borel T., Schwalm M., et al. Gastroprotection chez les patients sous AINS à risque de complications digestives : résultats d'une enquête observationnelle en médecine générale. Gastroenterol Clin Biol 32 (2008) A22
32. van der Linden M., Kuipers E.J., Sukel M.P., et al. Trends and determination of adequate gastroprotection in chronic NSAID prescription. Gut 56 (2007) A27
33. Singh G., Vadhavkar S., Mithal A., et al. A new safety warning: decreased gastroprotection is associated with an increase of serious ulcer complication in elderly users of NSAIDS. Gut 56 (2007) A28
34. Goldstein J.L., Howard K.B., Walton S.M., et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 4 (2006) 1337-1345
35. van Soest E.M., Sturkenboom M.C., Dieleman J.P., et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 26 (2007) 265-275
36. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
37. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338 (1998) 727-734
38. Yeomans N.D., Tulassay Z., Juhasz L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338 (1998) 719-726
39. Scheiman J.M., Yeomans N.D., Talley N.J., et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101 (2006) 701-710
40. Sachs G., Shin J.M., and Howden C.W. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23 Suppl. 2 (2006) 2-8
41. Lanza F.L., Chan F.K., and Quigley E.M. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104 (2009) 728-738
42. Woolf A.D., Zeidler H., Haglund U., et al. Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Ann Rheum Dis 63 (2004) 342-347
43. Singh G., Ramey D.R., Morfeld D., et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 156 (1996) 1530-1536
44. Yeomans N.D., Lanas A.I., Talley N.J., et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22 (2005) 795-801
45. Sung J., Lau J.Y., Ching J.Y., et al. Early reintroduction of aspirin with proton pump inhibitors after endoscopic hemostasis for peptic ulcer bleeding: final results of a double blinded randomized study. Gut 56 (2007) A27
46. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
47. Lai K.C., Chu K.M., Hui W.M., et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 4 (2006) 860-865
48. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
49. Hawkey C.J., Tulassay Z., Szczepanski L., et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 352 (1998) 1016-1021
50. Chan F.K., Sung J.J., Chung S.C., et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350 (1997) 975-979
51. Chan F.K., To K.F., Wu J.C., et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359 (2002) 9-13
52. Schaeverbeke T., Broutet N., Zerbib F., et al. Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. Am J Gastroenterol 100 (2005) 2637-2643
53. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
54. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
55. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528 [p. 1522 following 1528]
56. Laine L., Curtis S.P., Cryer B., et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369 (2007) 465-473
57. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
58. Targownik L.E., Metge C.J., Leung S., et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 134 (2008) 937-944
59. Goldstein J.L., Silverstein F.E., Agrawal N.M., et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 95 (2000) 1681-1690
60. Laine L., Connors L.G., Reicin A., et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124 (2003) 288-292
61. Laine L., Curtis S.P., Langman M., et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 135 (2008) 1517-1525
62. Chan F.K., Wong V.W., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369 (2007) 1621-1626
63. Lewis S.C., Langman M.J., Laporte J.R., et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 54 (2002) 320-326